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Abstract 
Although severe reactions to immunoglobulin preparations have been frequently reported, IgE antibodies against 
IgA are usually not investigated; and occur predominantly in previously sensitized patients. The purpose is to report 
anaphylaxis to IGIV during initial infusion in a patient with common variable immunodeficiency with absent IgA with-
out prior sensitization and in the absence of detectable IgG anti-IgA antibodies, and positive skin tests for immediate 
hypersensitivity to four different preparations of IGIV, one subcutaneous immunoglobulin preparation, and to purified 
IgA. Patient was treated without side effects with IGIV preparation depleted of IgA to which immediate hypersensitiv-
ity skin test was negative.
This case demonstrates that patients with CVID with no IgA and without prior exposure to immunoglobulin or plasma 
may develop anaphylaxis following initial infusion of IGIV, which appears to be due to IgE anti-IgA, and independ-
ent of IgG anti-IgA antibodies. Since there is no good correlation between anaphylaxis/anaphylactic reactions and 
IgG anti-IgA antibodies, and IgE anti-IgA antibody test is commercially unavailable, we suggest that the patients with 
CVID with absence of IgA might be skin tested for immediate hypersensitivity prior to initiation of immunoglobulin 
administration. However, such recommendation may require studies on a large number of patients with CVID with no 
detectable IgA.
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Background
Common variable immunodeficiency (CVID) is a hetero-
geneous disorder characterized by decreased levels of at 
least two immunoglobulin isotypes, including IgG and 
impaired specific antibody response [1]. Anaphylactic/
anaphylactic reactions to blood and plasma transfusion 
have been reported in subjects with IgG anti-IgA anti-
bodies [2, 3]. Immunoglobulin is the standard of care for 
antibody deficiency syndromes. Current practice does 
not specify the use of any specific immunoglobulin prep-
aration or testing prior to infusion. Infrequently patients 
develop systemic sensitivity to intravenous immunoglob-
ulin (IGIV) treatment, including anaphylaxis/anaphylac-
tic reactions, which may be associated with IgG-anti-IgA 
antibodies and often associated with prior exposure to 
immunoglobulin therapy [4, 5]. In contrast, patients with 
hypogammaglobulinemia and IgG anti-IgA antibod-
ies have tolerated immunoglobulin therapy without 
any reaction [6]. Therefore, there is a lack of correlation 
between IgG anti-IgA antibodies and anaphylactic/ana-
phylaxis reaction [4, 7]. A few cases have been reported 
in whom IgE-mediated anaphylaxis developed following 
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immunoglobulin therapy [4, 8]. However, these patients 
were receiving and tolerating immunoglobulin prior to 
development of anaphylaxis. We report a patient with 
common variable immunodeficiency (CVID) with no 
detectable IgA and naïve to immunoglobulin therapy, 
who developed what appears to be IgE anti-IgA antibody 
mediated, and IgG anti-IgA independent anaphylaxis 
during initial 5 min of first IGIV infusion.
Case description
A 37  year-old male with a history of chronic ear infec-
tions throughout childhood, and childhood asthma and 
rhinitis was referred to immunology clinic for an evalu-
ation. Since the age of 15  years, he is having 2–3 epi-
sodes of bronchitis per year, developed recurrent otitis 
media requiring myringotomy tubes, and suffered six 
image-proven sinus infections in the previous 2  years. 
In 2013, he was hospitalized twice for pneumonia. He 
has no history of receiving prior blood or blood product 
transfusions. In 8/2014, a diagnosis of common variable 
immunodeficiency (CVID) was confirmed. His labora-
tory findings are shown in Table 1. Gammagard 10 % IV 
infusion was started at the rate of 30 cc/h. Within 5 min 
of starting IGIV, patient reported tightness of chest, diffi-
culty in breathing, facial flushing, bilateral wheezes, pulse 
rate of 126/min, severe rigor, and oxygen saturation drop 
to 86  %. Patient was given IV famotidine, IV meperi-
dine, IV hydrocortisone, IV Benadryl, and Oxygen at 6 L. 
Patient was skin tested for various IGIV and subcutane-
ous Ig preparations along with purified IgA and normal 
saline. On 2/11/2015, Patient was given graded dosage of 
IgA-depleted IGIV (Gammagard SD) preparation (5, 10, 
30 ml) to which skin test was negative, with premedica-
tion of prednisone, Benadryl, and acetaminophen orally 
an hour prior to infusion. He tolerated the infusion with-
out any side effects. Patient tolerated infusion at 80 ml/h 
rate. Patient has no history of allergies to pollen, food, or 
drugs.
Methods and results
This study was approved by the Institution Review Board 
(Human), University of California, Irvine. Consent was 
obtained from the patient.
Serum immunoglobulins, complement levels, and IgG 
anti-IgA antibodies were performed were Department of 
Pathology, University of California, Irvine. Serum Immu-
noglobulins were performed by nephelometry. Lympho-
cyte subsets were performed with anti-CD3, anti-CD4, 
anti-CD8, anti-CD19, anti-CD16, and anti-CD56 mono-
clonal antibodies and corresponding isotype controls 
(Pharmingen BD Sciences, San Jose, California) using 
FACSCalibur (Becton–Dickinson, San Jose, California). 
10,000 cells were acquired and analysis was performed 
with FlowJo software (Treestar, Ashland, Oregon). 
Patient has extremely low levels of all immunoglobulin 
and normal functional CH50 and normal levels of CD3 
and C4 complements. T cells, T cell subsets, B cells and 
natural killers are present in normal proportions and 
numbers.
Because patient has a true anaphylaxis and had unde-
tectable serum IgG anti-IgA antibodies, it was reasoned 
that his anaphylaxis was most likley IgE-mediated. 
Patient was skin tested for immediate hypersensitivity 
with four different IGIV preparations and one immuno-
globulin subcutaneous preparation (IGSC). All prepara-
tions except Octagam (1:10 dilution because high IgA 
content) were used undiluted. Furthermore to establish 
that immediate hypersensitivity reactions are against IgA 
in various preparations, skin tests were also performed 
with purified IgA (Sigma, St. Louis, MO) and preparation 
of IGIV that has negligible amount of IgA.
Data in Table 2 demonstrates positive wheal/flare reac-
tions to various IGIV and IGSC preparations, indicating 
IgE-mediated sensitivity to Immunoglobulin prepara-
tions. Furthermore, patient had positive wheal/flare reac-
tion within 15 min to purified human IgA indicating that 
positive reactions to all commercially available prepara-
tions tested were most likely due to IgE anti-IgA antibod-
ies. The patient was then skin tested with Gammagard SD 
Table 1 Immunological profile of the patient
Laboratory test Patient’s value Reference value
IgG <33 mg/dl 694–1618 m/dl
IgA (mg/dl) <6.7 68–378
IgM (mg/dl) <4.2 65–263
IgE (IU/ml) <1 10–150
IgG anti-IgA antibody (U/ml) <16 <99
Complement Total, CH50 (U/ml) 137 101–300
Complement, C3 (mg/dl) 120 88–201
Complement, C4 (mg/dl) 27 16–47
Total WBC count 8000/3ml 4000–10,500/3ml
Lymphocytes,  % 25 14–44
Total lymphocytes 2000/3ml 900–3300/3ml
CD3 + CD4+ % 37 31–61
CD3 + CD4+ 740/3ml 338–1194/3ml
CD3 + CD8+ % 35 10–38
CD3 + CD8+ 700/3ml 85–729/3ml
CD4: CD8 ratio 1.06 0.9–3.7
CD3, % 78 62–84
CD3, total 1560/3ml 619–1847/3ml
CD19, % 17 5–26
CD19, total 340/3ml 51–473/3ml
CD56, % 4 1–17
CD56, total 80/3ml 12–349/3ml
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(very low IgA) and no local reaction was observed, simi-
lar to normal saline.
Discussion
Anaphylaxis upon first exposure is rare, and generally 
requires sensitization via prior exposure to an antigen, 
or a structurally related antigen, which may induce cross-
reactivity. Patients with CVID who have a history of 
severe adverse reactions to IGIV therapy most frequently 
are those with undetectable levels of IgA. The pathophys-
iology is attributed to immune complexes of IgG anti-
IgA antibodies resulting in complement activation and 
manifesting as anaphylaxis/anaphylactic reactions upon 
exposure to IGIV therapy, which includes variable con-
centrations of contaminating IgA [9].
The prevalence of IgG anti-IgA antibodies in patients 
with CVID has been reported as high as 9  % [10]. A 
patient with CVID, who tolerated immunoglobulin intra-
muscular for 6 years and two IGIV infusions, developed 
a severe anaphylactic reaction during third IGIV infusion 
[11]. This was associated with the presence of IgG anti-
IgA antibodies, immune complexes, and evidence of com-
plement activation. This patient tolerated IgA-depleted 
IGIV. However, there is no good correlation between 
IgG anti-IgA antibodies and anaphylactic reaction; IgG 
anti-IgA antibodies have been observed in CVID patients 
with undetectable IgA [12] and normal IgA [7] without 
any systemic reaction to IGIV. In our patient, IgG anti-
IgA antibodies were absent, and CH50, C3, and C4 were 
normal; however, we did not perform C3 split products 
to completely exclude a possibility of complement acti-
vation. Since our patient has no IgG anti-IgA antibodies, 
therefore, unlikely to have circulating immune complexes 
to activate complement. Furthermore, IgE does not fix the 
complement, therefore, immune complex-mediated acti-
vation of complement appears to be unlikely a mechanism 
for anaphylaxis in our patient. Finally, complement-medi-
ated activation of mast cell is associated with delayed skin 
induration and flare and not immediate as observed with 
IgE-mediated immediate hypersensitivity.
True IgE-mediated anaphylaxis to IGIV preparations is 
exceedingly rare and usually requires prior sensitization. 
Since IgE antibodies against IgA are usually not investi-
gated, frequency of IgE-mediated anaphylaxis to IVIG in 
CVID is not known.
Burks and colleagues [8] reported anaphylaxis in two 
patients with CVID with absence of IgA. First patient 
developed anaphylaxis after 5th intramuscular injec-
tion of immunoglobulin (prior sensitization), and second 
patient developed anaphylaxis following initial infusion 
of plasma from the patient’s father, which would contain 
normal levels of IgA, almost 100 fold higher than immu-
noglobulin preparations. Both serum IgG anti-IgA and 
IgE anti-IgA antibodies were detected by ELISA assay. 
However, presence of IgE anti-IgA antibodies in one of 
these two patients could not be replicated [12]. Ferreira 
et al. [13] reported presence of a IgE anti-IgA in a patient 
with CVID, who later developed anaphylaxis with IGIV. 
In another study, Ferreira and associates [7] reported 
presence of IgE anti-IgA antibodies in a patient with 
hyper IgM syndrome; however, it was unclear whether 
this patient received immunoglobulin therapy and if 
received how he/she tolerated it.
Our patient was distinct from all these patients in that 
he was naïve to immunoglobulin, and had no circulating 
IgG anti-IgA antibodies. Finally, he had positive immedi-
ate hypersensitivity skin test reactions to four different 
preparations of IGIV, one subcutaneous Immunoglobu-
lin, and to purified IgA, establishing that his anaphylaxis 
was most likely IgE anti-IgA-mediated. However, sur-
prisingly we did not find correlation between the size of 
wheel or flare with the concentrations of IgA in various 
IGIV and IGSC preparations. Immediate hypersensitivity 
skin test reaction was negative to Gammagard S/D (very 
low concentration of IgA), a preparation, which he later 
tolerated given intravenously, and normal saline. Inter-
estingly, our patient has very low serum IgE, which sug-
gest that either traces of serum IgE has anti-IgA activity 
or most of IgE anti-IgA antibodies are mast cell associ-
ated, and very little free antibody in the serum. It has 
been demonstrated that a single glycan on IgE is indis-
pensible for initiation of anaphylaxis [14]. This patient 
highlights that anaphylaxis can occur in the presence of 
very low serum IgE. A possibility of the presence of pos-
sible mast cell-associated IgE anti-IgA in the absence of 
circulating IgE anti-IgA might also explain a lack of cor-
relation between size of wheal and flare reactions with 
preparations of immunoglobulin with various concentra-
tions of IgA.
Limaye et  al. [15] reported a patient with CVID and 
undetectable levels of IgA, who developed anaphylaxis 
twice to blood products. Prior to starting IGIV, patient 
was skin tested with two different IVIG concentrations 
Table 2 Patient’s immediate hypersensitivity intradermal 
skin tests
Immunoglobulin preparations Wheal (in mm) Flare (in mm)
Gammagard liquid 37 ug/ml 9 58
Hizentra 50 ug/ml 18 80
Privigen 25 ug/ml 21 78
Octagam 200 ug/ml 10 60
Gammagard-S/D <1 ug/ml 2 3
Purified human IgA 10 ug/ml 10 25
Normal saline 3 4
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and report positive skin test with IGIV products con-
taining high concentrations of IgA but negative skin to a 
product with very low concentrations of IgA. They also 
did not measure IgE anti-IgA antibodies. Patient with 
Burk et  al. [8] also had both IgG anti-IgA and IgE anti-
IgA antibodies. In our patient, there were no IgG anti-
IgA antibodies.
Bjorkander et al. [12] observed IgG anti-IgA antibodies 
in 74 immunodeficiency patients with undetectable IgA, 
8 of them received low IgA containing IGIV (IgA <20 ug/
ml), one of the patients developed anaphylaxis, whereas 
other tolerated IGIV infusions. None of them had IgE 
anti-IgA. It is possible that skin test for immediate hyper-
sensitivity may provide more sensitive test than ELISA 
or radioimmunoassay; this would be especially true for 
patient, who may have predominantly mast cell-associ-
ated IgE anti-IgA antibodies with negligible amounts in 
the serum. It is well known that skin tests are more sen-
sitive than serological immunoassays for allergens. The 
precise sensitivity of these immunoassays compared 
with prick/puncture skin tests has been reported to be 
approximately 70–75 %. In most situations, skin tests are 
therefore the most clinically useful tests for the diagnosis 
of IgE-mediated sensitivity [16]. It is unlikely that positive 
skin tests were due to an non-specific irritation. Control 
saline and Gammagard S/D were negative in the patient. 
We have performed skin tests in three other patients with 
CVID with negative results.
Since there is no good correlation between IgG anti-
IgA antibodies and anaphylaxis, no recommendation to 
screen for these antibodies, and no commercially avail-
able IgE ELISA assay for IgE anti-IgA antibodies, we pro-
pose that patients with CVID and absent IgA may be skin 
tested for immediate hypersensitivity with immunoglob-
ulin preparation prior to initial infusion. In those patients 
with positive reactions, immunoglobulin preparation 
with very low IgA content may be used. It can be argued 
that why not administer Gammagard-SD in immunode-
ficiency patients with undetectable IgA without going 
through skin testing. The reason is that Gammagard-SD 
comes in the powder form and has to be reconstituted 
under strict sterile condition, which may not be avail-
able in outpatient or private office settings. Furthermore, 
Gammagard-SD contains sugar as preservative, has high 
osmolarity, and hence, greater possibility of renal side 
effects of IGIV. Therefore, use of Gammagard-SD should 
be restricted to those patients, who demonstrate positive 
skin test to immunoglobulin preparation to be used.
Conclusions
We suggest that the patients with CVID with absence 
of IgA, even those naïve to immunoglobulin or 
plasma products, may be skin tested for immediate 
hypersensitivity to immunoglobulin preparations prior to 
initiation of immunoglobulin administration. In case of 
positive skin test, an IgA-depleted preparation of immu-
noglobulin may be used to minimize a possibility of ana-
phylactic reaction. However, a study of large number of 
patients with CVID and undetectable IgA is needed prior 
to making it as a universal recommendation.
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